Multicenter prospective phase II trial of nivolumab in patients with unresectable or metastatic mucosal melanoma

ConclusionAlthough this trial met the primary endpoint, the RR was still unsatisfactory. Therefore, further treatment development is required.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research